197 results about "Stromal cell" patented technology

Disclosed is a method for producing T cells, the method comprising: (1) culturing three-dimensional cell aggregate(s) comprising cells that can differentiate into T cells, and stromal cells that express Notch ligand(s) derived from pluripotent stem cells. Also disclosed are T cells obtained by the method, and a medicine comprising the T cells.

The invention relates to the technical field of biology, and particularly provides an endometrial organ culture method. By optimizing the endometrial organoid differentiation culture system, compared with an existing culture mode, the optimized culture system is easy to operate, the organoid with more complete physiological functions can be prepared without co-culture with stromal cells, continuous culture can be conducted for at least one year or above, and the obtained organoid is complete in secretion function and free of secondary pollution. The phenotype of cilia cells is more obvious.

The present invention relates to a method for preparing organ-specific mesenchymal cells from pluripotent stem cell-derived intestinal organoid stromal cells. By using cells derived from stromal cell layers adjacent to intestinal organoids for differentiation into organ-specific mesenchymal cells, the present invention can greatly increase the efficiency of differentiation into stromal cells through the regulation of retinoic acid (RA) and hedgehog (HH) signaling pathways, and can increase the expression of organ-specific markers without exhibiting undifferentiated state cell characteristics, and thus mesenchymal cells having well-simulated biological characteristics can be prepared.

The invention discloses a bionic bone marrow microenvironment assembly for hematopoietic stem cell in-vitro amplification and a preparation method. The bone marrow microenvironment assembly comprises a three-dimensional scaffold and osteoblasts (OBs), wherein the three-dimensional scaffold comprises chitosan (CS) and sodium alginate (Alg) which are prepared into mixed gel, and the mixed gel is freeze-dried to prepare the three-dimensional scaffold; wherein the osteoblasts (OBs) are obtained by culturing and induced differentiation of umbilical cord mesenchymal stem cells (MSCs) inoculated on a three-dimensional scaffold, and the osteoblasts (OBs) as stromal cells and the three-dimensional scaffold jointly form the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly; in the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly, the preparation of the three-dimensional scaffold comprises the processes of freezing, remelting, freezing, crosslinking, freeze-drying and the like, so that a three-dimensional space form with wrinkles on the pore surface and pore size distribution between 70 microns and 400 microns is generated in the three-dimensional scaffold, and the three-dimensional space form is closer to a real stem cell niche; therefore, the practical application effect of the bionic bone marrow microenvironment assembly for in-vitro amplification of the hematopoietic stem cells is further improved.

The present invention provides a method of producing a population of mesenchymal stromal cells (MSC) of CD73 + CD44 +, CD90 +. The CD73 + CD44 +, CD90 + MSC is used in a method for producing terminally differentiated osteoblasts, adipoblasts and chondroblasts from pluripotent stem cells (PSCs). The differentiation methods include the use of a single agent-a WNT signaling pathway activator used on an adherent culture of PSC, such as a GSK3 [beta] inhibitor.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

It was discovered that by binding to CTCF which is important for maintaining chromosomal structures, hSATII RNA inhibits the function thereof, changes chromosome interaction, and induces transcription of inflammation-associated genes. It has also been discovered that cell death can be selectively induced in senescent cells and cancer cells by suppressing hSATII RNA expression. From the obtained results, it has been found that cancer treatment which targets senescent stromal cells and cancer cells can be performed with a substance that suppresses hSATII RNA or a substance that increases CTCF expression. In addition, cancer can be detected early by measuring the expression and activity of hSATII RNA and CTCF, and an epigenomic change of the hSATII DNA region. Thus, it is possible to provide a therapeutic drug for a cancer associated with cellular senescence, a method for screening thereof, and a test support method.

Methods of differentiating a mesenchymal stromal cell (MSC) to a first non-MSC cell fate, the method comprising contacting the MSC with extracellular vesicles (EVs), matrix-bound vesicles (MBVs) or a combination thereof are provided. Methods of producing artificial tissue by culturing MSCs with two sets of vesicles each comprising EVs, MBVs or both that differentiate MSCs to two different non-MSC cell fates, methods of culturing with reduced growth factors and method of differentiating an MSC to a muscle cell fate are also provided.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative / healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The present invention discloses a microfluidic chip and its construction method and application. A microfluidic chip of the present invention includes a polydimethylsiloxane layer and a base layer, the polydimethylsiloxane layer contains three or more microchannels; the microchannels are connected by a plurality of parallel microgrooves; the microchannels are provided with channels connected to the outside world; the base layer is at least one of a glass base, a polydimethylsiloxane base or a polystyrene base. The preparation method of the microfluidic chip of the present invention is simple and can achieve co-culture of tumor nerve cells. The pancreatic cancer-neural-stromal cell microenvironment model constructed using the microfluidic chip of the present invention can achieve the co-construction of the pancreatic cancer stromal microenvironment and the neural microenvironment, and can also perform qualitative and quantitative evaluation of nanomedicines targeting the neural microenvironment and the stromal microenvironment, which plays an important role in the screening of drugs related to the treatment of pancreatic cancer.

The present invention relates to the use of mesenchymal stem cells (MSCs) for enhancing the immune response of elderly or animal subjects to vaccination. According to the application, the defects of spleen stromal cell networks and lymphocyte structures of old subjects can be repaired by applying the MSC in advance, and the immune level of organisms is improved; and the vaccine is injected after a period of time, so that the specific antibody level after vaccine immunization can be improved. The effect can also significantly prevent the elderly subjects from being infected by influenza. Therefore, the MSC has a good application prospect in solving related immune decline of old people.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The invention belongs to the technical field of biology, and provides stromal cell hydrogel as well as a preparation method and application thereof. The stromal cell hydrogel is obtained by crosslinking stromal cells modified by azido groups N3, multi-arm polyethylene glycol and polyethylene glycol N3-PEG2K-N3 modified by diazido groups. According to the invention, the stromal cells are used as a gel component for tumor organoid or 3D culture for the first time. The living cells are used as a gel material, a tumor microenvironment is highly simulated, growth factors necessary for in-vitro culture of the tumor cells are provided, and the matrix cell hydrogel truly restores an in-vivo 3D culture environment. In addition, the matrix cell hydrogel can be used for patient PDX cell culture and can be used for large-scale drug screening.

The invention belongs to the technical field of biological materials, and particularly relates to a pathogen-targeted engineered exosome as well as a preparation method and application thereof. The engineered exosome provided by the invention comprises an adipose-derived stromal cell exosome, antibacterial peptide M27-39 and 6 '-sialic acid lactose, and integrates two functions of resisting influenza virus and relieving viral pneumonia, targeted modification of 6'-SL can simulate a host receptor structure, and binding of HA and sialic acid is competitively blocked. After the antibacterial peptide M27-39 carried by the exosome is released in the lung, the direct antiviral effect can be achieved, excessive inflammatory response induced by viruses is inhibited, and meanwhile lung injury caused by influenza virus infection is relieved by promoting alveolar epithelial cell repair and relieving pathological injury of viral pneumonia. Therefore, the engineered exosome provided by the invention can be combined with pathogenic microorganisms in a targeted manner, and has obvious functions of resisting pathogenic microorganisms, resisting inflammation, repairing barriers and intervening the pathological process of infectious lung injury.

This invention belongs to the field of biomedical technology, specifically relating to the application of mesenchymal stem cells in the preparation of anti-aging drugs. The mesenchymal stem cells are human adipose-derived mesenchymal stem cells (hAMSCs) or mouse bone marrow mesenchymal stem cells (BM-MSCs). This invention utilizes mesenchymal stem cells to regulate senescent stromal cells and the spleen's ECM, improving the thinning stromal state in the tissue microenvironment through multiple targets. Specifically, it improves the aging-related secretory phenotype of stromal cells, enhances mitochondrial activity, strengthens their proliferation capacity, and delays the reduction of collagen secretion. This, in turn, delays the disordered distribution and functional decline of immune cells caused by aging and enhances tissue regeneration capacity, indirectly affecting various other cells in the tissue microenvironment, thus exhibiting an antagonistic effect against systemic organ aging.

The invention discloses an application of a JAM3 modified engineered vesicle in preparation of a medicine for treating bone injury, the JAM3 modified engineered vesicle is prepared, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on bone marrow mesenchymal stem cells (BMSCs) is proved through ALP staining, RT-qPCR, WB and other experiments at the cellular level, so that the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved. Meanwhile, the effect of JAM3 modified engineered vesicles on promoting osteogenesis of bone defect mice is defined through in-vivo experiments. According to the invention, osteogenesis direction differentiation and bone formation capability of BMSC can be promoted, and bone formation capability of bone defect mice can be promoted in vivo; the compound can be used for treating related diseases such as bone injury.

Normal hematopoiesis relies on a dynamic, interactive network of stromal cell types that secrete a variety of growth factors and cytokines. Two of the most intensely studied molecules implicated in the interaction between HSPCs and stromal cells is the CXCL12 / CXCR4 signaling pair. Mutations resulting in impaired desensitization and enhanced CXCR4 signaling have been identified in the WHIM Syndrome (WS). Hereby, we use a mouse model harboring a WS-linked Cxcr4 gain-of-function mutation (CXCR4 C1013G ), along with a unique and robust co-culture model between primary MSCs and lymphoid-primed MPP (or MPP4). We report functional alterations in MSCs lacking Cxcr4 desensitization, affecting their interaction with MPP4 and interfering with their lymphoid / myeloid specification. In addition, using a human MSC cell line transduced with another WS-linked CXCR4 gain-of-function mutation (CXCR4 R334X ), we show that these genetically engineered MSCs also promoted the myeloid differentiation of human primary HSPCs.

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and / or decreasing the amount of TGFβR2, and / or decreasing the amount of and / or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

The invention provides application of an immune response biomarker in prognosis evaluation of mesenchymal stromal cells in treatment of liver cirrhosis patients, and relates to the technical field of biomedicine, the immune response biomarker comprises MX1 positive monocytes or / and LGALS2 positive monocytes, and the MX1 positive monocytes are MX1 positive monocytes or / and LGALS2 positive monocytes. Screening to obtain a potential biomarker LGALS2 positive mononuclear cell and an MX1 positive mononuclear cell for predicting the MSC treatment dose-effect relationship; compared with a healthy control, the proportion of baseline MX1 positive monocytes of a liver cirrhosis patient is remarkably increased (Plt; 0.01), while the proportion of LGALS2 positive monocytes is significantly reduced (Plt; 0.05) of the substrate (1); the change trend of the biomarker under the same MSC dose and the regulation effect on other immune cell subgroups are identified through sequencing analysis, the dose-effect relationship of MSC-mediated immune regulation can be accurately reflected, and patients with low MSC treatment prognosis recurrence risk can be identified.

The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells (hCT-MSCs) to treat Autism Spectrum Disorder. The methods involve treating a patient having or suspected of having an Autism Spectrum Disorder by administering a therapeutically effective amount of hCT-MSCs.

Provided herein are artificial lung organoids. The artificial lung organoids may include an epithelial cell layer comprising mammalian lung epithelial cells, a stromal cell layer comprising mammalian lung fibroblast cells and an endothelial cell layer comprising mammalian endothelial cells. The artificial lung organoids may optionally include a porous membrane between said epithelial cell layer and said stromal cell layer and / or between said stromal cell layer and said endothelial lung cell layer.

The present application relates to the technical field of biological medicine, and more particularly to a culture solution, a kit and an application for in-vitro maturation of aged oocytes. Through in-vitro experiments, the present application adds exogenous stromal cell-derived factor 1, establishes a culture system for in-vitro maturation of aged oocytes, and reveals the molecular mechanism of stromal cell-derived factor 1 playing a role through autophagy, thereby providing a new solution for improving the fertility of aged women and improving the success rate of assisted reproductive technology, and having important clinical application value.

The present disclosure relates to allogeneic populations of mesenchymal stem / stromal cells and related compositions, which populations and compositions comprise cells pooled from multiple donors, and their use in therapy and / or prevention of inflammatory, autoimmune, transplant related and CNS disorders, in particular CNS such as Amyotrophic Lateral Sclerosis. The present disclosure also relates to methods for obtaining said compositions.

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

The present disclosure provides a use of salvianolic acid E (SAE) in the preparation of drugs targeting senescent cells, inhibiting tumors or prolonging lifespan. The inventors are committed to research in screening drugs targeting tumor microenvironment, enhancing the anti-tumor effect of chemotherapeutic drugs, eliminating senescent cells or restraining cellular senescence. Here, it is revealed that salvianolic acid E exerts its effects by targeting tumor microenvironment and eliminating senescent cells. When combined with chemotherapeutic drugs, it shows extremely significant effects in promoting tumor suppression by removing senescent stromal cells. For a senescence-associated secretory phenotype (SASP), the SAE can also effectively target senescent cells so as to inhibit the SASP. Besides, the SAE can also significantly prolong the life of animals, significantly extend the survival period of the old and improve the life quality of animals.